证券代码：300204 证券简称：舒泰神 公告编号：2025-081 舒泰神（北京）生物制药股份有限公司 关于换发药品生产许可证及营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、舒泰神（北京）生物制药股份有限公司（以下简称"公司"）于近期取 得了北京市药品监督管理局换发的药品生产许可证，主要信息如下： 企业名称：舒泰神（北京）生物制药股份有限公司 北京市北京经济技术开发区经海二路 36 号：口服溶液剂、散剂、片剂、治 疗用生物制品*** 社会信用代码：911100007423131451 注册地址：北京市北京经济技术开发区经海二路 36 号 法定代表人：周志文 企业负责人：王超 质量负责人：刘晓宁 有效期至：2030 年 11 月 02 日 许可证编号：京 20150112 分类码：AhsBsCs 生产地址和生产范围： 北京市北京经济技术开发区瑞合西一路 7 号院（北京昭衍生物技术有限公 司）：治疗用生物制品*** 二、基于上述药品生产许可证信息，根据《药品生产监督管理办法》的要求， 公司向北京经济技术开发区市场监督管理局申请换发了营业执照 ...

Core Points - The Shanghai Composite Index is at 3948.89 points with a slight increase of 0.05% as of 10:33 AM, and the total trading volume of A-shares is 851.994 billion yuan [1] - A total of 98 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish trends [1] Group 1: Stocks with Significant Moving Average Crosses - Bawei Storage (688525) has a 5-day moving average of 122.55 yuan, which is 2.96% lower than its 10-day moving average of 126.29 yuan, with a current price of 113.88 yuan, down 3.24% today [1] - Jinkai Biological (301509) shows a 5-day moving average of 37.52 yuan, down 1.69% from its 10-day moving average of 38.17 yuan, currently priced at 34.13 yuan, down 6.49% [1] - Shutaishen (300204) has a 5-day moving average of 35.59 yuan, which is 1.41% lower than its 10-day moving average of 36.09 yuan, with a current price of 33.40 yuan, down 2.34% [1] Group 2: Additional Stocks with Moving Average Crosses - Tongli Rising (605286) has a 5-day moving average of 42.55 yuan, down 1.39% from its 10-day moving average of 43.14 yuan, currently priced at 40.40 yuan, down 0.20% [1] - Ziran (605080) shows a 5-day moving average of 24.27 yuan, which is 1.25% lower than its 10-day moving average of 24.58 yuan, currently priced at 23.43 yuan, down 1.88% [1] - Yema Battery (605378) has a 5-day moving average of 25.22 yuan, down 1.23% from its 10-day moving average of 25.53 yuan, currently priced at 24.03 yuan, down 0.62% [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"）第六届董事会第 十一次会议审议通过了《关于提请召开公司 2025 年第三次临时股东会的议案》， 本次股东会将于 2025 年 11 月 24 日采用现场表决与网络投票相结合的方式召开。 《关于召开 2025 年第三次临时股东会的通知》已于 2025 年 11 月 07 日刊登于中国 证监会指定的创业板信息披露网站。现将会议有关事项提示如下： 一、召开会议的基本情况 证券代码：300204 证券简称：舒泰神 公告编号：2025-080 舒泰神（北京）生物制药股份有限公司 关于召开 2025 年第三次临时股东会的提示性公告 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市 公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关 规定。 4、会议时间： （1）现场会议时间：20 ...

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.02% on November 19, with a trading price of 34.02 CNY per share, reflecting a significant drop in recent trading days despite a substantial year-to-date increase of 359.11% [1] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of biological products and some chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (Sutai) at 59.17%, compound polyethylene glycol electrolyte powder at 33.19%, and others at 7.63% [1] - The company was established on August 16, 2002, and went public on April 15, 2011 [1] Financial Performance - For the period from January to September 2025, Shuyou Shen reported an operating income of 181 million CNY, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million CNY, a decline of 227.71% [2] - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 46,500, a rise of 46.97%, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings by the third-largest shareholder, Xingquan Helun Mixed A, by 3.45 million shares, and an increase in holdings by the fifth-largest shareholder, Xingquan Heyi Mixed A, by 338,750 shares [3] Market Activity - The stock has seen significant trading activity, with a net outflow of 29.42 million CNY from major funds on November 19, and it has appeared on the trading leaderboard eight times this year, with the most recent instance on October 31, where it recorded a net buy of 373 million CNY [1]

截至11月17日收盘，创新药概念下跌1.72%，位居概念板块跌幅榜前列，板块内，科兴制药、舒泰神、 昂利康等跌幅居前，股价上涨的有33只，涨幅居前的有富祥药业、海南海药、百花医药等，分别上涨 12.14%、10.04%、8.63%。 | 603858 | 步长制药 | -2.89 | 0.96 | -906.39 | | --- | --- | --- | --- | --- | | 301075 | 多瑞医药 | -2.17 | 1.99 | -894.32 | | 301408 | 华人健康 | -2.92 | 22.50 | -887.82 | | 600479 | 千金药业 | -1.90 | 1.87 | -871.50 | | 000597 | 东北制药 | -1.54 | 1.20 | -835.15 | | 002099 | 海翔药业 | 1.1 1 | 1.30 | -831.28 | | 301333 | 诺思格 | -1.53 | 3.36 | -788.71 | | 300575 | 中旗股份 | 0.15 | 2.31 | -781.84 | | 300026 | 红日药业 | -1 ...

Group 1 - The cell immunotherapy sector experienced a decline of 1.87%, ranking among the top losers in the concept sector, with companies like Shutaishen, Jimin Health, and Puris leading the declines [1][2] - Among the concept stocks, Baohua Pharmaceutical, ST Zhongzhu, and Laimei Pharmaceutical saw the highest gains, with increases of 8.63%, 4.80%, and 0.93% respectively [1][3] - The cell immunotherapy sector faced a net outflow of 1.658 billion yuan, with 54 stocks experiencing net outflows, and 8 stocks seeing outflows exceeding 50 million yuan [1][2] Group 2 - The top net outflow stocks in the cell immunotherapy sector included Shutaishen with a net outflow of 284.46 million yuan, followed by Hengrui Medicine, Hanyu Pharmaceutical, and Fosun Pharmaceutical with outflows of 236.06 million yuan, 124.39 million yuan, and 104.04 million yuan respectively [1][2] - Conversely, the stocks with the highest net inflows included Baohua Pharmaceutical, Boji Pharmaceutical, and Yuekang Pharmaceutical, with inflows of 79.05 million yuan, 13.46 million yuan, and 4.04 million yuan respectively [1][3] - The trading volume for Shutaishen was 12.35%, indicating significant trading activity despite the decline in stock price [2][3]

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.44% on November 17, with Shuyatong leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Top Gainers in Chemical Pharmaceutical Sector - Fuxiang Pharmaceutical (300497) saw a closing price of 21.15, with a significant increase of 12.14% and a trading volume of 1.8867 million shares, amounting to a transaction value of 3.8 billion [1] - Muanhai Pharmaceutical (000566) closed at 7.45, up 10.04%, with a trading volume of 2.5684 million shares, totaling 1.871 billion [1] - Kangzhiyue Pharmaceutical (300086) closed at 11.11, increasing by 4.61%, with a trading volume of 1.5735 million shares, amounting to 1.747 billion [1] Top Losers in Chemical Pharmaceutical Sector - Buzou Pharmaceutical (300204) closed at 36.31, down 7.61%, with a trading volume of 560,200 shares, resulting in a transaction value of 2.067 billion [2] - Anglikang (002940) closed at 43.43, decreasing by 7.60%, with a trading volume of 251,600 shares, totaling 1.112 billion [2] - Aozhu Pharmaceutical (002755) closed at 18.59, down 5.59%, with a trading volume of 260,100 shares, amounting to 489 million [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 3.72 billion from institutional investors, while retail investors saw a net inflow of 2.604 billion [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Jingxin Pharmaceutical (002020) had a net inflow of 21.78 million from institutional investors, while retail investors experienced a net outflow of 13.49 million [3] - Taiankang (301263) saw a net inflow of 13.83 million from institutional investors, with retail investors facing a net outflow of 26.79 million [3] - Meinuohua (603538) recorded a net inflow of 12.13 million from institutional investors, while retail investors had a net outflow of 17.35 million [3]

Core Viewpoint - The company Shuyou Shen (300204) has its conditional listing application for the injectable STSP-0601 accepted by the National Medical Products Administration (NMPA) in June 2025, currently undergoing the normal review process [1] Group 1 - The priority review and approval process for the listing registration application has a review time limit of 130 days [1] - Preliminary reviews by various professional departments have been completed, and the process has entered the next stage, indicating that the review is progressing normally [1] - The review and approval for STSP-0601 has not concluded, and updates on research and development projects will be provided in future regular reports and project progress announcements [1]

Core Viewpoint - The company Shutaishen (300204.SZ) has submitted a conditional listing application for its injectable STSP-0601, which was accepted by the National Medical Products Administration (NMPA) in June 2025 and is currently undergoing the normal review process [1] Group 1 - The priority review application for STSP-0601 has a review timeline of 130 days [1] - Preliminary reviews by various professional departments have been completed, and the application has entered the next stage [1] - The timing for the Center for Drug Evaluation (CDE) is currently paused, indicating that the review process is proceeding normally and has not concluded [1]

Core Points - The company Shuotai Shen (300204.SZ) has provided an update regarding the conditional listing application for its injectable STSP-0601, which was accepted by the National Medical Products Administration (NMPA) in June 2025 and is currently undergoing the normal review process [2] - The priority review timeline for the listing registration application is set at 130 days, and the preliminary review by various professional departments has been completed, leading to a temporary suspension of the CDE's timing, which is part of the normal review process [2] - The review and approval process for STSP-0601 has not concluded, and stakeholders are encouraged to monitor future regular reports and project progress announcements for updates [2]